PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
877.13%
Revenue growth of 877.13% while CRON.TO is flat. Bruce Berkowitz would check if a small edge can widen further.
177.09%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
-20.78%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-20.78%
Negative operating income growth while CRON.TO is at 575.95%. Joel Greenblatt would press for urgent turnaround measures.
83.07%
Net income growth under 50% of CRON.TO's 542.15%. Michael Burry would suspect the firm is falling well behind a key competitor.
83.25%
EPS growth under 50% of CRON.TO's 935.85%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
83.25%
Diluted EPS growth under 50% of CRON.TO's 935.85%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.59%
Share reduction more than 1.5x CRON.TO's 22.56%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.59%
Diluted share reduction more than 1.5x CRON.TO's 22.56%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
54.66%
OCF growth under 50% of CRON.TO's 176.96%. Michael Burry might suspect questionable revenue recognition or rising costs.
39.94%
FCF growth 75-90% of CRON.TO's 45.59%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1466.81%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-1466.81%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1466.81%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-86.27%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-86.27%
Negative 5Y net income/share CAGR while CRON.TO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-86.27%
Negative 3Y CAGR while CRON.TO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
147.79%
Equity/share CAGR of 147.79% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
147.79%
Equity/share CAGR of 147.79% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
147.79%
Equity/share CAGR of 147.79% while CRON.TO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.22%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
92.35%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.72%
Negative asset growth while CRON.TO invests at 49.63%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.67%
We have a declining book value while CRON.TO shows 27.39%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-68.21%
We cut SG&A while CRON.TO invests at 176.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.